Dr. O’Malley on the unmet need for bladder cancer clinical trial funding
“I think research is a very important tool,” says Padraic O’Malley, MD, MSc, FRCSC.
In this video, Padraic O’Malley, MD, MSc, FRCSC, discusses the takeaway of the study, “Gender disparities in the clinical trials and real-world utilization of systemic therapy in the management of urothelial carcinoma,” which was presented recently at the Society of Women in Urology Annual Clinical Mentoring Conference. O’Malley is an assistant professor in the department of urology at the University of Florida in Gainesville.
Updates on advanced bladder cancer treatment
October 30th 2023"If a patient begins treatment with platinum-based chemotherapy and maintenance immune checkpoint inhibition, second-line options may involve evaluating erdafitinib, ADCs, or participation in clinical trials," says Adanma Ayanambakkam, MD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
